ReproCELL Expects Synergy and Business Benefits through the Acquisitions of Reinnervate and BioServe

ReproCELL (JASDAQ:4978) was established as a venture company originating from the University of Tokyo and Kyoto University and has been the pioneer in the iPS cell business, succeeding in the commercialization of the world's first human iPS cell products in 2009 and with the world's most advanced research and technology.

Through the acquisitions of Reinnervate Limited (Reinnervate, located in Europe) and BioServe Biotechnologies, Ltd. (BioServe, located in the United States), ReproCELL Group will accelerate its iPS cell business through the following synergistic effects:

1. The Establishment of Global Distribution Network
ReproCELL, Reinnervate and BioServe already serve the same types of customers including large pharmaceutical companies, biotechnology companies, major universities and medical institutions in Europe and the United States, respectively. The local sales and distribution expertise provided by Reinnervate and BioServe will help grow ReproCELL’s market share in Europe and North America. ReproCELL’s local presence in Japan and extensive distribution networks in Asia will help to accelerate sales of Reinnervate and BioServe products in Asia.

2. Technology synergy and new product introductions
(1) Next Generation iPS cell products
Through the combination of Reinnervate’s innovative 3D cell culture technologies and ReproCELL’s iPS cell technologies, the next generation of iPS cell products with better functionality and usability for customers will be developed and launched globally.

(2) Patients-derived iPS Cell Products
Through the acquisition of BioServe, ReproCELL will now have access to large variety of patient derived cells in disease areas such as Alzheimer's, Parkinsons and Cardiovascular disorders. This will accelerate the development and commercialization of diverse patient-derived iPS cell products where there is a rapidly growing market need.

ReproCELL will now aggressively promote both existing and new products derived from these technology synergies and leverage best practices from all three businesses in all territories.

[Reference]
Reinnervate Company Outline
Reinnervate is a 2002 spin-out company from Durham University, a center of excellence in cell biology research located in County Durham, UK. Reinnervate’s Alvetex platform is based on the research performed by Prof. Stefan Przyborski. Professor Przyborski is considered to be one of the world’s leading experts in the field of 3D cell culture and as is Reinnervate’s Chief Scientific Officer, in addition to his role as Professor of Cell Technology in the School of Biological and Biomedical Science at Durham University. Reinnervate is a leader in the fast-growing market of 3D cell culture. Alvetex 3D cell culture enables scientist to grow tissue-like structures that better mimic in vivo biology than current 2D monolayer methods. The potential to improve the predictive nature of cell based assays by combining 3D culture and iPSC-derived cell products is attracting a lot of interest in the drug development industry.
Reinnervate’s products have a wide range of applications in drug discovery screening and academic research and are currently used by researchers in over 300 universities and companies globally.
URL: http://reinnervate.com/

BioServe Company Outline
BioServe was established in 1989 by researchers including Dr. Rama Modali, who worked for NIH (National Institute of Health) and National Cancer Institute as a molecular biologist. Located in Beltsville MD, USA, BioServe reposits human biomaterials more than 600,000 samples including human DNA, organ and serum samples, providing researchers in Universities and Pharmaceutical Companies. BioServe has over 500 customers including large pharmaceutical companies, biotechnology companies, diagnostic service companies, major universities and medical institutions.
URL: http://www.bioserve.com/